A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Recruiting
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home vi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Novo Nordisk Investigational Site, Indianapolis, Indiana
Conditions: Diabetes Mellitus, Type 2, Obesity
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/17/2023
Locations: St. Vincents Hospital, Indianapolis, Indiana
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Kidney and Hypertension Center of Wabash Valley LLC, Terre Haute, Indiana
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Afrezza® INHALE-1 Study in Pediatrics
Recruiting
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine in combination with a basal insulin (i.e., the Rapid-acting Insulin Analog [RAA] injection group) in pediatric subjects with type 1 or type 2 diabetes mellitus. Following 26 weeks of randomized treatment (i.e., Afrezza or RAA injection combined with a basal insulin), all... Read More
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
11/07/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Recruiting
The purpose of this study is to assess the safety and PK of teplizumab in participants with Stage 2 type 1 diabetes who are <8 years of age.
Gender:
All
Ages:
Between 0 years and 7 years
Trial Updated:
11/03/2023
Locations: Clinical Site 110, Indianapolis, Indiana
Conditions: Type 1 Diabetes
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
Recruiting
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2023
Locations: Indiana University School of Medicine, Indianapolis, Indiana +1 locations
Conditions: NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
STOP-T1D Low-Dose (ATG)
Recruiting
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
Gender:
All
Ages:
Between 12 years and 34 years
Trial Updated:
10/27/2023
Locations: Indiana University - Riley Hospital for Children, Indianapolis, Indiana
Conditions: Diabetes Mellitus, Type 1
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
Recruiting
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
10/27/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Diabetes Mellitus, Type 1
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
Recruiting
This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine. The study will also test if semaglutide is safe in children and teenagers. Participants will either get semaglutide or the dummy medicine - which one is decided by chance. Participants will take 1 tablet of the study medicine every morning on an empty stomach. They have to wait 30 minutes before they ea... Read More
Gender:
All
Ages:
Between 10 years and 18 years
Trial Updated:
10/26/2023
Locations: Novo Nordisk Investigational Site, Indianapolis, Indiana
Conditions: Diabetes Mellitus, Type 2
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
Recruiting
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: Assess the efficacy of foselutoclax compared to aflibercept Assess the safety and tolerability of foselutoclax
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Midwest Eye, Carmel, Indiana
Conditions: Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
Incorporating Mind-body Skills With Diabetes Education in Adolescents With Type 1 Diabetes
Recruiting
Adolescence presents a challenging time for type 1 diabetes management, and despite a multitude of studies aimed at increasing disease compliance in this age group, none have been deemed superior. The purpose of this study is to incorporate mindfulness skills in with diabetes education sessions for adolescents with type 1 diabetes and study if this translates to improved outcomes in glycemic control, patient satisfaction, and mental wellness.
Gender:
All
Ages:
Between 15 years and 17 years
Trial Updated:
10/24/2023
Locations: Indiana University Health Methodist Hospital, Indianapolis, Indiana +1 locations
Conditions: Type 1 Diabetes, Adolescent Behavior
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
Recruiting
This is a multicenter randomized clinical trial of 828 overweight and obese individuals with gestational diabetes designed to compare standard to intensive glycemic targets.
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
10/23/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Gestational Diabetes, Pregnancy, High Risk, Overweight and Obesity